LNTH Lantheus Holdings
$99.95 -0.24%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-0.24%
YTD
+92.80%
P/E
23.71
P/B
4.05
ROE
23.3%
Div yield
—
Beta
0.57
Market cap
$6.5B
RSI (14)
45
Next earnings
Oct 29, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$100.28
Close
$99.95
VWAP (n/a)
—
Day high
$100.33
Day low
$99.89
Volume
730K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Yahoo Finance · Sep 30
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Yahoo Finance · Sep 28
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
Yahoo Finance · Sep 26
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
Yahoo Finance · Sep 26
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
Yahoo Finance · Sep 23
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Yahoo Finance · Sep 22
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Oct 2, 2026 View → 8-K Sep 21, 2026 View → 10-Q Aug 6, 2026 View → 8-K Aug 6, 2026 View → 8-K Aug 4, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell LNTH. Try it in the Lab to size a position and see the risk.